Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
54 hedge funds and large institutions have $153M invested in Unity Biotechnology in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 27 closing their positions.
4,220% more call options, than puts
Call options by funds: $4.15M | Put options by funds: $96K
535% more capital invested
Capital invested by funds: $24.1M → $153M (+$129M)
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
31.2% more ownership
Funds ownership: 4.35% → 35.55% (+31%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
25% less funds holding
Funds holding: 72 → 54 (-18)
63% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFVM
Founders Fund V Management
San Francisco,
California
|
+$1.29M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$162K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$145K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$142K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$88.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.71M |
| 2 |
ACM
Altium Capital Management
New York
|
-$1.69M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$489K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$291K |
| 5 |
Millennium Management
New York
|
-$241K |
UBX Hedge Fund Activity: Q4 2022 in Review
54 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2022, worth a combined $153M — up 535% from $24.1M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of UBX and 10 opened new positions — a net loss of 17 holders — while 11 trimmed existing stakes and 23 added.
The largest buyer was Founders Fund V Management, adding an estimated $1.29M. The largest seller was Alyeska Investment Group, cutting an estimated $1.71M.
- 54 institutional investors held Unity Biotechnology (UBX) as of Q4 2022, down from 72 in Q3 2022.
- Funds reported $153M of Unity Biotechnology stock for Q4 2022, up 535% quarter-over-quarter.
- 10 funds opened new Unity Biotechnology positions in Q4 2022 and 27 closed out, a net change of -17 holders.
- The largest Unity Biotechnology buyer in Q4 2022 was Founders Fund V Management, an estimated $1.29M added.
- The largest Unity Biotechnology seller in Q4 2022 was Alyeska Investment Group, an estimated $1.71M sold.
Based on aggregated 13F filings for Q4 2022.